Biocytogen Entered into an Agreement with CtM Biotech to Co-develop TCR-Mimic Antibody-Based Multi-Specific T Cell Engagers for Cancer
Shots:
- Under the terms of the agreement, the companies collaborated to develop novel Ab products & expand the potential of immunotherapy to improve the lives of patients suffering from cancer and other debilitating diseases
- Additionally, the agreement provides assess to CtM Bio to use Biocytogen's T cell engager platform to co-develop T cell engagers targeting intracellular tumor-associated Ag for cancer patients. Biocytogen will be responsible for screening fully human Abs against specific targets using the TCR-mimic Ab development platform
- Biocytogen's TCR-mimic Ab development platform uses a strain of fully human RenMab mice expressing an HLA gene to discover Abs against intracellular tumor-associated Ag
Ref: PR Newswire | Image: Biocytogen
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
